title: In vivo pharmacology of BIIR 561 CL, a novel combined antagonist of AMPA receptors and voltage-dependent Na(+) channels.
abstract: Glutamate receptors of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype and voltage-gated Na(+) channels are associated with diseases of the central nervous system characterized by neuronal over-excitation as in epilepsy or cerebral ischaemia. In animal models, AMPA receptor antagonists and Na(+) channel blockers provide protection in these conditions. Dimethyl-[2-[2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-phenoxyl]-ethyl]-amine hydrochloride (BIIR 561 CL) combines both, AMPA receptor - and Na(+) channel blocking properties in one molecule. Here, BIIR 561 CL was investigated in vivo. BIIR 561 CL protected mice against AMPA-induced toxicity with an ED(50) value of 4.5 mg kg(-1) following subcutaneous (s.c.) administration. A 0.1% solution of BIIR 561 CL provided local anaesthesia in the corneal reflex test in rabbits. In mice, the compound prevented tonic seizures in the maximal electroshock (MES) model with an ED(50) value of 3.0 mg kg(-1) s.c. In amygdala-kindled rats, BIIR 561 CL inhibited seizures at doses of 3 and 11 mg kg(-1) following intraperitoneal (i.p.) injection. The data show that the combination of blocking AMPA receptor- and voltage-gated Na(+) channels in one molecule induces effective protection in animal models of neuronal over-excitation.
authors.affiliation: Boehringer Ingelheim, Ingelheim, Germany. wienrich@ing.boehringer-ingelheim.com
authors.forename: M
authors.initials: M
authors.lastname: Wienrich
authors.forename: M
authors.initials: M
authors.lastname: Brenner
authors.forename: W
authors.initials: W
authors.lastname: Löscher
authors.forename: R
authors.initials: R
authors.lastname: Palluk
authors.forename: M
authors.initials: M
authors.lastname: Pieper
authors.forename: H
authors.initials: H
authors.lastname: Potschka
authors.forename: T
authors.initials: T
authors.lastname: Weiser
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology; D001569:Benzodiazepines; D003643:Death; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D005260:Female; D007928:Lethal Dose 50; D008297:Male; D008801:Mexiletine / Q000494:pharmacology; D051379:Mice; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010069:Oxadiazoles / Q000494:pharmacology*; D011810:Quinoxalines / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D026941:Sodium Channel Blockers; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology
chemical_list: D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D018696:Neuroprotective Agents; D010069:Oxadiazoles; D011810:Quinoxalines; D018091:Receptors, AMPA; D026941:Sodium Channel Blockers; C061950:GYKI 52466; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D001569:Benzodiazepines; D008801:Mexiletine; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; C119322:irampanel